U.S. Markets closed

Esperion Therapeutics has reached compelling entry point, says Stifel

After meeting with Esperion's management, Stifel thinks the company is poised to report "compelling" Phase 2b data in Q4 for its ETC-1002 for statin-intolerant patients. The firm believes that the data will cause other companies to have strong interest in partnering with Esperion ,and it thinks the company has a large commercial opportunity. It keeps a Buy rating on the shares.